Why is that? It’s not as if the company was solely focused on COVID. Moderna has had other R&D projects in the pipeline and has diversified enough to weather the declining interest in COVID vaccines. I’m genuinely puzzled by such a steep decline. It has to be a leadership or management issue, because I can’t see any other clear explanation.
There are no replies in this thread yet. Be the first to post a reply below: